Novo Nordisk closed the trading week with a bang, its shares surging 6.66 percent to €35.16 on Friday. The jump offers a welcome reprieve for investors who have watched the stock shed roughly 21 percent since the start of the year. Yet beneath the surface of that single-day rally lies a far more complex story — one of regulatory relief, a quiet lobbying overhaul, and a looming Medicare price hammer.
The catalyst for Friday’s gains came from an unexpected corner: the logistics chain. The European Medicines Agency has loosened transport rules for the blockbuster weight-loss shot Wegovy, allowing it to be stored at temperatures up to 30 degrees Celsius for as long as 48 hours on the final delivery leg. That flexibility slashes the need for an unbroken cold chain, cutting distribution costs and making the supply network across Europe far more efficient. For a company struggling to keep pace with insatiable demand for its GLP-1 drugs, the change is a meaningful operational win.
Novo Nordisk is pouring billions into production capacity to match that demand. In France, €2.1 billion is flowing into the Chartres site, where output is set to double by 2028. The company is also retrofitting a plant in Athlone, Ireland, for €432 million to manufacture oral semaglutide formulations, while a separate project in Montes Claros, Brazil, is spending 8 billion Danish kroner on sterile filling lines.
But while the European logistics picture brightens, the US market is darkening fast. The US government has selected semaglutide — the active ingredient in both Ozempic and Wegovy — for Medicare price negotiations under the Inflation Reduction Act. Starting in 2027, Ozempic will be capped at $274 per month, a dramatic cut from the current list price of $959. Higher Wegovy doses will face a $385 monthly ceiling. Novo Nordisk has challenged the policy in court, so far without success. The third federal appeals court dismissed the company’s lawsuit along with those of other drugmakers, though the US Chamber of Commerce has filed an amicus brief with the Supreme Court, keeping the legal avenue open.
That price pressure is already reshaping Novo Nordisk’s Washington playbook. The company quietly parted ways on February 1 with Public Strategies Washington, a Democratic-aligned lobbying firm that had spent three and a half years pushing for better Medicare and Medicaid coverage of obesity drugs. The move is not a retreat from lobbying — Novo Nordisk still spends more than $8 million annually on such efforts, and its in-house team alone reported nearly $1.3 million in first-quarter 2026 outlays. Rather, it signals a strategic pivot: out goes the Democratic-linked shop, in come firms with stronger Republican ties, including S-3 Group LLC, Nickles Group, and Ballard Partners.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The financial stakes will come into sharp focus on May 6, when Novo Nordisk reports first-quarter results before the market opens. Management has already warned that 2026 will bring a 5 to 13 percent decline in adjusted revenue and profit, driven by US pricing pressure and patent expirations in certain markets. CEO Mike Doustdar has called this “the year of price pressure,” pledging to offset the hit with volume gains and acquisitions. Analysts expect quarterly revenue to edge just above $11 billion.
Technically, the stock remains deeply oversold, with the RSI indicator sitting at a low 17.8 points. Analyst price targets vary wildly: Sanford Bernstein sees the shares at $175, while Goldman Sachs pegs a more modest $41. From the 52-week high of €70.13, the stock is still down nearly 50 percent.
On the commercial front, the oral version of semaglutide for type 2 diabetes is expected to launch in the US during the second quarter. And a voluntary Medicare demonstration program called BALANCE, offering limited GLP-1 access, kicks off in July 2026, opening to Medicaid participants as early as May. It is a partial fix, not a permanent legislative solution.
The May 6 numbers will reveal whether volume growth can truly plug the hole left by Washington’s price squeeze — and whether Novo Nordisk’s logistical and political recalibrations are enough to steady a ship that has taken on considerable water.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from April 26 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 26.
Novo Nordisk: Buy or sell? Read more here...
